Last reviewed · How we verify
Placebo for 5% Minoxidil Foam
This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials for minoxidil foam efficacy.
This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials for minoxidil foam efficacy. Used for Placebo control for androgenetic alopecia (male pattern hair loss) trials.
At a glance
| Generic name | Placebo for 5% Minoxidil Foam |
|---|---|
| Sponsor | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations are inert vehicles designed to match the appearance, texture, and administration method of the active drug being tested, allowing for blinded comparison in clinical trials. In this case, it mimics 5% minoxidil foam but contains no minoxidil or other active agents. Placebo controls help isolate the true therapeutic effect of minoxidil from psychological and environmental factors.
Approved indications
- Placebo control for androgenetic alopecia (male pattern hair loss) trials
Common side effects
- Minimal expected adverse events (inert formulation)
Key clinical trials
- Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia (PHASE3)
- Treatment of Androgenetic Alopecia in Men for 24 Weeks (PHASE3)
- Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss (PHASE3)
- Clinical Trial in Females for Female Pattern Hair Loss (PHASE3)
- Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: